ABSTRACT
PURPOSE: Glioblastoma is an aggressive central nervous system tumor with a 5-year survival rate of < 10%. The standard therapy for glioblastoma is maximal safe resection, followed by radiation therapy and chemotherapy with temozolomide. New approaches to treatment of glioblastoma, such as targeting metabolism, have been studied. The object of this study is to evaluate whether asparagine could be a new target for treatment of glioblastoma. METHODS: We investigated a potential treatment for glioblastoma that targets the amino acid metabolism. U251, U87, and SF767 glioblastoma cells were treated with L-asparaginase and/or 6-diazo-5-oxo-L-norleucine (DON). L-asparaginase hydrolyzes asparagine into aspartate and depletes asparagine. L-asparaginase has been used for the treatment of acute lymphoblastic leukemia. DON is a glutamine analog that inhibits several glutamine-utilizing enzymes, including asparagine synthetase. RESULTS: Cell viability was measured after 72 h of treatment. MTS assay showed that L-asparaginase suppressed the proliferation of U251, U87, and SF767 cells in a dose-dependent manner. DON also inhibited the proliferation of these cell lines in a dose-dependent manner. Combined treatment with these drugs had a synergistic antiproliferative effect in these cell lines. Exogenous asparagine rescued the effect of inhibition of proliferation by L-asparaginase and DON. The expression of asparagine synthetase mRNA was increased in cells treated with a combination of L-asparaginase and DON. This combined treatment also induced greater apoptosis and autophagy than did single-drug treatment. CONCLUSION: The results suggest that the combination of L-asparaginase and DON could be a new therapeutic option for patients with glioblastoma.
Subject(s)
Antineoplastic Agents/administration & dosage , Asparaginase/administration & dosage , Brain Neoplasms/metabolism , Diazooxonorleucine/administration & dosage , Glioblastoma/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , HumansABSTRACT
6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist with robust anticancer efficacy; however, its therapeutic potential was hampered by its biodistribution and toxicity to normal tissues, specifically gastrointestinal (GI) tissues. To circumvent DON's toxicity, we synthesized a series of tumor-targeted DON prodrugs designed to circulate inert in plasma and preferentially activate over DON in tumor. Our best prodrug 6 (isopropyl 2-(6-acetamido-2-(adamantane-1-carboxamido)hexanamido)-6-diazo-5-oxohexanoate) showed stability in plasma, liver, and intestinal homogenates yet was readily cleaved to DON in P493B lymphoma cells, exhibiting a 55-fold enhanced tumor cell-to-plasma ratio versus that of DON and resulting in a dose-dependent inhibition of cell proliferation. Using carboxylesterase 1 knockout mice that were shown to mimic human prodrug metabolism, systemic administration of 6 delivered 11-fold higher DON exposure to tumor (target tissue; AUC0- t = 5.1 nmol h/g) versus GI tissues (toxicity tissue; AUC0- t = 0.45 nmol h/g). In summary, these studies describe the discovery of a glutamine antagonist prodrug that provides selective tumor exposure.
Subject(s)
Antineoplastic Agents/administration & dosage , Diazooxonorleucine/administration & dosage , Drug Delivery Systems , Lysine/chemistry , Prodrugs/chemistry , Acetylation , Animals , Area Under Curve , Carboxylic Ester Hydrolases/genetics , Cell Line, Tumor , Diazooxonorleucine/pharmacokinetics , Humans , Mice , Mice, Knockout , SwineABSTRACT
The deadliest complication of Plasmodium falciparum infection is cerebral malaria (CM), with a case fatality rate of 15 to 25% in African children despite effective antimalarial chemotherapy. No adjunctive treatments are yet available for this devastating disease. We previously reported that the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) rescued mice from experimental CM (ECM) when administered late in the infection, a time by which mice had already suffered blood-brain barrier (BBB) dysfunction, brain swelling, and hemorrhaging. Herein, we used longitudinal MR imaging to visualize brain pathology in ECM and the impact of a new DON prodrug, JHU-083, on disease progression in mice. We demonstrate in vivo the reversal of disease markers in symptomatic, infected mice following treatment, including the resolution of edema and BBB disruption, findings usually associated with a fatal outcome in children and adults with CM. Our results support the premise that JHU-083 is a potential adjunctive treatment that could rescue children and adults from fatal CM.
Subject(s)
Diazooxonorleucine/antagonists & inhibitors , Diazooxonorleucine/therapeutic use , Glutamine/antagonists & inhibitors , Magnetic Resonance Imaging/methods , Malaria, Cerebral/drug therapy , Malaria, Cerebral/pathology , Malaria, Falciparum/drug therapy , Malaria, Falciparum/pathology , Adult , Animals , Antimalarials/therapeutic use , Biomarkers , Blood-Brain Barrier/pathology , Brain/parasitology , Brain/pathology , Brain Edema/diagnostic imaging , Brain Edema/pathology , Child , Diazooxonorleucine/administration & dosage , Disease Models, Animal , Disease Progression , Female , Humans , Malaria, Cerebral/diagnostic imaging , Malaria, Cerebral/parasitology , Malaria, Falciparum/diagnostic imaging , Mice , Mice, Inbred C57BL , Plasmodium falciparum/pathogenicityABSTRACT
Aberrant excitatory neurotransmission associated with overproduction of glutamate has been implicated in the development of HIV-associated neurocognitive disorders (HAND). The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON, 14) attenuates glutamate synthesis in HIV-infected microglia/macrophages, offering therapeutic potential for HAND. We show that 14 prevents manifestation of spatial memory deficits in chimeric EcoHIV-infected mice, a model of HAND. 14 is not clinically available, however, because its development was hampered by peripheral toxicities. We describe the synthesis of several substituted N-(pivaloyloxy)alkoxy-carbonyl prodrugs of 14 designed to circulate inert in plasma and be taken up and biotransformed to 14 in the brain. The lead prodrug, isopropyl 6-diazo-5-oxo-2-(((phenyl(pivaloyloxy)methoxy)carbonyl)amino)hexanoate (13d), was stable in swine and human plasma but liberated 14 in swine brain homogenate. When dosed systemically in swine, 13d provided a 15-fold enhanced CSF-to-plasma ratio and a 9-fold enhanced brain-to-plasma ratio relative to 14, opening a possible clinical path for the treatment of HAND.
Subject(s)
Aminocaproates/pharmacology , Azo Compounds/pharmacology , Diazooxonorleucine/pharmacology , Neurocognitive Disorders/drug therapy , Nootropic Agents/pharmacology , Prodrugs/pharmacology , Aminocaproates/administration & dosage , Aminocaproates/chemical synthesis , Animals , Azo Compounds/administration & dosage , Azo Compounds/chemical synthesis , Blood/metabolism , Brain/metabolism , Diazooxonorleucine/administration & dosage , Drug Stability , Female , Glutamic Acid/metabolism , Glutaminase/antagonists & inhibitors , HIV Infections/complications , Humans , Male , Mice, Inbred C57BL , Neurocognitive Disorders/etiology , Nootropic Agents/administration & dosage , Nootropic Agents/chemical synthesis , Prodrugs/administration & dosage , Prodrugs/chemical synthesis , Swine , Viral Load/drug effectsABSTRACT
Infection of weanling C57BL/6 mice with the TE strain of Sindbis virus (SINV) causes nonfatal encephalomyelitis associated with hippocampal-based memory impairment that is partially prevented by treatment with 6-diazo-5-oxo-l-norleucine (DON), a glutamine antagonist (Potter et al., J Neurovirol 21:159, 2015). To determine the mechanism(s) of protection, lymph node and central nervous system (CNS) tissues from SINV-infected mice treated daily for 1 week with low (0.3mg/kg) or high (0.6mg/kg) dose DON were examined. DON treatment suppressed lymphocyte proliferation in cervical lymph nodes resulting in reduced CNS immune cell infiltration, inflammation, and cell death compared to untreated SINV-infected mice. Production of SINV-specific antibody and interferon-gamma were also impaired by DON treatment with a delay in virus clearance. Cessation of treatment allowed activation of the antiviral immune response and viral clearance, but revived CNS pathology, demonstrating the ability of the immune response to mediate both CNS damage and virus clearance.
Subject(s)
Alphavirus Infections/drug therapy , Alphavirus Infections/immunology , Antiviral Agents/administration & dosage , Diazooxonorleucine/administration & dosage , Encephalomyelitis/drug therapy , Encephalomyelitis/immunology , Glutamine/antagonists & inhibitors , Sindbis Virus/physiology , Alphavirus Infections/pathology , Alphavirus Infections/virology , Animals , Encephalomyelitis/pathology , Encephalomyelitis/virology , Humans , Interferon-gamma/genetics , Interferon-gamma/immunology , Male , Mice , Mice, Inbred C57BL , Sindbis Virus/drug effectsABSTRACT
Mosquito-borne viruses are important causes of death and long-term neurologic disability due to encephalomyelitis. Studies of mice infected with the alphavirus Sindbis virus have shown that outcome is dependent on the age and genetic background of the mouse and virulence of the infecting virus. Age-dependent susceptibility reflects the acquisition by neurons of resistance to virus replication and virus-induced cell death with maturation. In mature mice, the populations of neurons most susceptible to infection are in the hippocampus and anterior horn of the spinal cord. Hippocampal infection leads to long-term memory deficits in mice that survive, while motor neuron infection can lead to paralysis and death. Neuronal death is immune-mediated, rather than a direct consequence of virus infection, and associated with entry and differentiation of pathogenic T helper 17 cells in the nervous system. To modulate glutamate excitotoxicity, mice were treated with an N-methyl-D-aspartate receptor antagonist, α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor antagonists or a glutamine antagonist. The N-methyl-D-aspartate receptor antagonist MK-801 protected hippocampal neurons but not motor neurons, and mice still became paralyzed and died. α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor antagonists GYKI-52466 and talampanel protected both hippocampal and motor neurons and prevented paralysis and death. Glutamine antagonist 6-diazo-5-l-norleucine protected hippocampal neurons and improved memory generation in mice surviving infection with an avirulent virus. Surprisingly, in all cases protection was associated with inhibition of the antiviral immune response, reduced entry of inflammatory cells into the central nervous system, and delayed virus clearance, emphasizing the importance of treatment approaches that include prevention of immunopathologic damage.
Subject(s)
Alphavirus Infections/drug therapy , Encephalomyelitis/drug therapy , Encephalomyelitis/virology , Neurons/virology , Sindbis Virus/physiology , Alphavirus Infections/immunology , Alphavirus Infections/prevention & control , Alphavirus Infections/virology , Animals , Benzodiazepines/administration & dosage , Cell Death , Diazooxonorleucine/administration & dosage , Dizocilpine Maleate/administration & dosage , Encephalomyelitis/immunology , Encephalomyelitis/prevention & control , Hippocampus/drug effects , Hippocampus/virology , Humans , Inflammation/metabolism , Memory/drug effects , Mice , Neurons/drug effects , Neurons/immunology , Neurons/metabolism , Receptors, AMPA/antagonists & inhibitors , Receptors, AMPA/physiology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/physiology , Sindbis Virus/pathogenicity , Survival Analysis , Th17 Cells/metabolismABSTRACT
There is a strong rationale for targeting the metabolic alterations of cancer cells. The most studied of these are the higher rates of glycolysis, glutaminolysis and de novo synthesis of fatty acids (FAs). Despite the availability of pharmacological inhibitors of these pathways, no preclinical studies targeting them simultaneously have been performed. In the present study it was determined whether three key enzymes for glycolysis, glutaminolysis and de novo synthesis of FAs, hexokinase-2, glutaminase and fatty acid synthase, respectively, were overexpressed as compared to primary fibroblasts. In addition, we showed that at clinically relevant concentrations lonidamine, 6-diazo-5-oxo-L-norleucine and orlistat, known inhibitors of the mentioned enzymes, exerted a cell viability inhibitory effect. Genetic downregulation of the three enzymes also reduced cell viability. The three drugs were highly synergistic when administered as a triple combination. Of note, the cytotoxicity of the triple combination was low in primary fibroblasts and was well tolerated when administered into healthy BALB/c mice. The results suggest the feasibility and potential clinical utility of the triple metabolic targeting which merits to be further studied by using either repositioned old drugs or newer, more selective inhibitors.
Subject(s)
Fatty Acid Synthases/biosynthesis , Glutaminase/biosynthesis , Hexokinase/biosynthesis , Neoplasms/drug therapy , Animals , Apoptosis/drug effects , Cell Survival/drug effects , Diazooxonorleucine/administration & dosage , Drug Synergism , Fatty Acid Synthases/antagonists & inhibitors , Fatty Acids/metabolism , Fibroblasts/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Glutaminase/antagonists & inhibitors , Glycolysis/drug effects , Hexokinase/antagonists & inhibitors , Humans , Indazoles/administration & dosage , Lactones/administration & dosage , Metabolic Networks and Pathways/drug effects , Mice , Neoplasms/enzymology , Neoplasms/pathology , OrlistatABSTRACT
Neuroblastomas (NBL) and Ewing's sarcomas (EWS) together cause 18% of all pediatric cancer deaths. Though there is growing interest in targeting the dysregulated metabolism of cancer as a therapeutic strategy, this approach has not been fully examined in NBL and EWS. In this study, we first tested a panel of metabolic inhibitors and identified the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) as the most potent chemotherapeutic across all NBL and EWS cell lines tested. Myc, a master regulator of metabolism, is commonly overexpressed in both of these pediatric malignancies and recent studies have established that Myc causes cancer cells to become "addicted" to glutamine. We found DON strongly inhibited tumor growth of multiple tumor lines in mouse xenograft models. In vitro, inhibition of caspases partially reversed the effects of DON in high Myc expressing cell lines, but not in low Myc expressing lines. We further showed that induction of apoptosis by DON in Myc-overexpressing cancers is via the pro-apoptotic factor Bax. To relieve inhibition of Bax, we tested DON in combination with the Bcl-2 family antagonist navitoclax (ABT-263). In vitro, this combination caused an increase in DON activity across the entire panel of cell lines tested, with synergistic effects in two of the N-Myc amplified neuroblastoma cell lines. Our study supports targeting glutamine metabolism to treat Myc overexpressing cancers, such as NBL and EWS, particularly in combination with Bcl-2 family antagonists.
Subject(s)
Aniline Compounds/administration & dosage , Antimetabolites, Antineoplastic/administration & dosage , Bone Neoplasms/drug therapy , Diazooxonorleucine/administration & dosage , Glutamine/antagonists & inhibitors , Neuroblastoma/drug therapy , Sarcoma, Ewing/drug therapy , Sulfonamides/administration & dosage , Aniline Compounds/pharmacology , Animals , Antimetabolites, Antineoplastic/pharmacology , Apoptosis , Bone Neoplasms/metabolism , Caspases/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Diazooxonorleucine/pharmacology , Drug Synergism , Humans , Mice , Neuroblastoma/metabolism , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Proto-Oncogene Proteins c-myc/metabolism , Sarcoma, Ewing/metabolism , Sulfonamides/pharmacology , Xenograft Model Antitumor AssaysABSTRACT
UNLABELLED: The rapid growth of cancer cells is permitted by metabolic changes, notably increased aerobic glycolysis and increased glutaminolysis. Aerobic glycolysis is also evident in the hypertrophying myocytes in right ventricular hypertrophy (RVH), particularly in association with pulmonary arterial hypertension (PAH). It is unknown whether glutaminolysis occurs in the heart. We hypothesized that glutaminolysis occurs in RVH and assessed the precipitating factors, transcriptional mechanisms, and physiological consequences of this metabolic pathway. RVH was induced in two models, one with PAH (Monocrotaline-RVH) and the other without PAH (pulmonary artery banding, PAB-RVH). Despite similar RVH, ischemia as determined by reductions in RV VEGFα, coronary blood flow, and microvascular density was greater in Monocrotaline-RVH versus PAB-RVH. A sixfold increase in (14)C-glutamine metabolism occurred in Monocrotaline-RVH but not in PAB-RVH. In the RV working heart model, the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) decreased glutaminolysis, caused a reciprocal increase in glucose oxidation, and elevated cardiac output. Consistent with the increased glutaminolysis in RVH, RV expressions of glutamine transporters (SLC1A5 and SLC7A5) and mitochondrial malic enzyme were elevated (Monocrotaline-RVH > PAB-RVH > control). Capillary rarefaction and glutamine transporter upregulation also occurred in RVH in patients with PAH. cMyc and Max, known to mediate transcriptional upregulation of glutaminolysis, were increased in Monocrotaline-RVH. In vivo, DON (0.5 mg/kg/day × 3 weeks) restored pyruvate dehydrogenase activity, reduced RVH, and increased cardiac output (89 ± 8, vs. 55 ± 13 ml/min, p < 0.05) and treadmill distance (194 ± 71, vs. 36 ±7 m, p < 0.05) in Monocrotaline-RVH. Glutaminolysis is induced in the RV in PAH by cMyc-Max, likely as a consequence of RV ischemia. Inhibition of glutaminolysis restores glucose oxidation and has a therapeutic benefit in vivo. KEY MESSAGE: Patients with pulmonary artery hypertension (PAH) have evidence of cardiac glutaminolysis. Cardiac glutaminolysis is associated with microvascular rarefaction/ischemia. As in cancer, cardiac glutaminolysis results from activation of cMyc-Max. The specific glutaminolysis inhibitor DON regresses right ventricular hypertrophy. DON improves cardiac function and exercise capacity in an animal model of PAH.
Subject(s)
Glutamine/metabolism , Heart Ventricles/metabolism , Animals , Basic-Leucine Zipper Transcription Factors/genetics , Basic-Leucine Zipper Transcription Factors/metabolism , Carrier Proteins/genetics , Carrier Proteins/metabolism , Diazooxonorleucine/administration & dosage , Diazooxonorleucine/pharmacology , Disease Models, Animal , Familial Primary Pulmonary Hypertension , Glucose/metabolism , Glutamine/antagonists & inhibitors , Heart Ventricles/pathology , Hypertension, Pulmonary/etiology , Hypertrophy, Right Ventricular/complications , Hypertrophy, Right Ventricular/drug therapy , Hypertrophy, Right Ventricular/genetics , Hypertrophy, Right Ventricular/metabolism , Hypoxia , Male , Models, Biological , Oxidation-Reduction , Proto-Oncogene Proteins c-myc/genetics , Proto-Oncogene Proteins c-myc/metabolism , RatsABSTRACT
Glutamate (Glu) immunocytochemistry has been widely used to identify presumed gluergic neurons and synapses, but several problems related to the fact that Glu is both a synaptic transmitter and a compound used for metabolic purposes are still unsolved. One of these concerns the intense perikaryal staining observed in perfusion-fixed tissue. Phosphate-activated glutaminase, a key enzyme for the synthesis of releasable glutamate, is inhibited by the diazoketone 6-diazo-5-oxo-L-norleucine (DON), which greatly reduces glutamate release. In the present experiments, DON was either injected intraparenchymally or applied epipially to the sensorimotor cortex of adult Sprague-Dawley rats at concentrations of 0.25-1 mM. Both intraparenchymal and epipial applications of the chemical abolished Glu immunoreactivity in neuron perikarya. Adjacent sections processed for cytochrome oxidase histochemistry, for aspartate immunoreactivity, or stained with thionine showed no changes. The effects of DON application are reversible, as shown in a second series of experiments in which, after 30 min of DON application, animals were allowed to survive for 5-10 days. In these cases, Glu immunoreactivity in cortical neurons was identical to that observed in normal untreated animals. The results reported here suggest that Glu immunoreactivity demonstrated by the present procedure in neuron perikarya is mainly due to Glu produced via phosphate-activated glutaminase.
Subject(s)
Cerebral Cortex/metabolism , Diazooxonorleucine/pharmacology , Glutamates/metabolism , Neurons/metabolism , Animals , Cell Survival/drug effects , Cerebral Cortex/cytology , Cerebral Cortex/drug effects , Diazooxonorleucine/administration & dosage , Female , Glutamates/analysis , Glutamic Acid , Glutaminase/antagonists & inhibitors , Glutaminase/metabolism , Immunohistochemistry , Male , Microinjections , Neurons/cytology , Neurons/drug effects , Parietal Lobe/drug effects , Parietal Lobe/physiology , Phosphates/pharmacology , Rats , Rats, Sprague-DawleyABSTRACT
DON (6-diazo-5-oxo-L-norleucine), a glutamine antagonist, has been subjected to limited clinical trials since 1957. Use of the drug in adults has been curtailed due to sparse reports of effectiveness as well as its dose-limiting toxicities, i.e., severe nausea, vomiting and mucositis. In earlier studies, children given DON orally in combination with 6-mercaptopurine had significant prolongation of remission of acute leukemias during maintenance therapy. As DON is acid-labile and relatively unstable in solution, oral administration does not appear to be ideal for DON. In the trial described in this report, i.v. DON therapy was studied, using i.v. chlorpromazine to control vomiting, in 20 children, 17 of whom were evaluable following treatment at DON dose levels ranging from 150 mg/m2 to 520 mg/m2. Nausea and vomiting, the dose-limiting toxicity for adults, was controlled with chlorpromazine. Mucositis, which has also been observed in adults, did not occur in the children given DON i.v. A maximum tolerated dose was not defined; however, the projected maximum tolerated dose appears to be in excess of 450 mg/m2. DON was measured in plasma using a rapid-sampling HPLC procedure. The total body clearance, plasma t1/2, and area under the plasma concentration curve (AUC) were calculated using a noncompartmental method. The drug is rapidly cleared from plasma (t 1/2 = 3 h), and its volume of distribution is approximately twice that of total body water in children. These pharmacokinetic data, differ from that of adults reported by others. Specifically, the plasma t 1/2 for children is longer: total body clearance (Cl), and volume of distribution at steady state (Vss) are greater. In addition, no dose dependency of t 1/2, Cl or Vss was observed in this study, and the DON pharmacokinetics were linear and predictable. Five of nine children with acute leukemia showed improvement, though insufficient for classification as partial response, and five of eight children with solid tumors also showed improvement. Further trials using DON in combination with thiopurines or other agents appear indicated.
Subject(s)
Azo Compounds/pharmacokinetics , Diazooxonorleucine/pharmacokinetics , Neoplasms/drug therapy , Adolescent , Child , Child, Preschool , Diazooxonorleucine/administration & dosage , Diazooxonorleucine/adverse effects , Dose-Response Relationship, Drug , Drug Evaluation , Female , Humans , Injections, Intravenous , MaleABSTRACT
The toxicity of the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) administered as a 24 hour infusion has been evaluated. Studies of the clinical pharmacology of the drug have also been performed in 3 patients. The limiting toxicity of the drug was acute nausea, vomiting and diarrhea that was dose dependent in its severity and duration. The maximum tolerated dose was 600 mg/m2 over 24 hours. The other major toxicity was thrombocytopenia that was maximal 7-10 days after the completion of the infusion. The drug does not exhibit renal, hepatic or central nervous system toxicity. DON achieves steady state levels during these infusions and is eliminated by first order kinetics when the infusion is completed (t1/2 alpha = 1.81 h). The principal route of excretion is renal. A starting dose of 400 mg/m2 would be acceptable for Phase II studies of this drug administered on this schedule.
Subject(s)
Azo Compounds/toxicity , Diazooxonorleucine/toxicity , Adult , Aged , Diazooxonorleucine/administration & dosage , Diazooxonorleucine/blood , Digestive System/drug effects , Drug Evaluation , Female , Humans , Male , Middle AgedABSTRACT
Twenty-three patients with advanced colorectal carcinoma, previously treated with chemotherapy, were entered in a phase II trial of DON (6-Diazo-5-Oxo-L-Norleucine), an antagonist of L-glutamine. One of 14 adequately treated patients had a partial response of 6 weeks duration. The dose-limiting toxicity was nausea and vomiting; 48% of patients originally entered on the study withdrew because of vomiting. Myelosuppression was minimal, with only mild thrombocytopenia noted. The dose and schedule used in this study were beyond the maximally tolerated dose for many patients; future phase II studies of DON will be difficult to complete unless schedules and doses are found which result in less nausea and vomiting.
Subject(s)
Azo Compounds/administration & dosage , Carcinoma/drug therapy , Colonic Neoplasms/drug therapy , Diazooxonorleucine/administration & dosage , Rectal Neoplasms/drug therapy , Adult , Aged , Diazooxonorleucine/adverse effects , Drug Administration Schedule , Drug Evaluation , Humans , Middle Aged , Nausea/chemically induced , Vomiting/chemically inducedABSTRACT
6-Diazo-5-oxo-L-norleucine (DON), an L-glutamine antagonist, was administered to 25 evaluable patients with refractory advanced solid tumors in a phase I trial. A total of 58 evaluable courses of five daily iv injections every 3-4 weeks were given, at doses ranging from 7.5 to 90 mg/m2/day. The major dose-limiting toxicity was a syndrome of nausea, vomiting, malaise, and anorexia, which became severe at doses greater than 52.5 mg/m2/day. Diarrhea and stomatitis were less frequent. Hematologic toxicity included mild leukopenia with nadir on Day 6-8 and mild thrombocytopenia with nadir on Day 7-12. Transient decreases in serum calcium to 8.5--8.9 mg/dl were seen in seven of 12 patients receiving greater than or equal to 67.5 mg/m2/day. Dose reduction was required for all patients who received a course of DON at greater than 67.5 mg/m2/day, and a maximum tolerated total dose of 250 mg/m2 (50 mg/m2/day x 5) is suggested for this schedule. Mixed responses were seen in one patient with bladder carcinoma and in one with pulmonary adenocarcinoma.
Subject(s)
Azo Compounds/administration & dosage , Diazooxonorleucine/administration & dosage , Neoplasms/drug therapy , Diazooxonorleucine/toxicity , Drug Administration Schedule , Drug Evaluation , HumansABSTRACT
DON, a glutamine antagonist, was administered iv to 26 patients with advanced cancer either once every 3 wks or daily for 3 days every 3 wks to determine toxicity and to look for evidence of therapeutic effect. Total doses ranged from 150 to 600 mg/m2. The single-day schedule produced intolerable nausea and vomiting and no evidence of cytotoxicity at 450-550 mg/m2 given over 10 mins or over 4 hrs. On the 3-day schedule, patients had tolerable gastrointestinal toxic effects at total doses up to 480 mg/m2 given in three equally divided doses by 10-min infusion. This dose also produced cytotoxic activity manifested as transient mild leukopenia and, rarely, thrombocytopenia. No objective responses were seen. Analysis of the plasma elimination of DON demonstrated dose-dependent pharmacokinetic behavior. The parent compound was not detectable in the urine of any patient, indicating extensive metabolism of the drug.
Subject(s)
Azo Compounds/administration & dosage , Diazooxonorleucine/administration & dosage , Neoplasms/drug therapy , Diazooxonorleucine/adverse effects , Diazooxonorleucine/metabolism , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Evaluation , Female , Half-Life , Humans , Infusions, Parenteral , Injections, Intravenous , Male , Vomiting/chemically inducedABSTRACT
We conducted a phase I study of 6-diazo-5-oxo-L-norleucine given iv on a twice weekly schedule. Twenty-six evaluable patients received 31 courses of the drug. Doses ranged from 100 to 500 mg/m2. Nausea with vomiting was the dose-limiting toxic effect, transient thrombocytopenia was seen frequently, and mucositis occurred in 39% of the patients. No definite therapeutic responses were observed in 18 patients with measurable lesions. The recommended dose for phase II studies is 200-300 mg/m2 iv twice weekly.